Count | |
| 10 | |
| 24 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
Epoprostenol/antagonists & inhibitors/*biosynthesis/metabolism | 1 |
| 1 | |
| 17 | |
| 2 | |
| 3 | |
| 10 | |
| 25 | |
| 1 | |
| 2 | |
| 3 | |
| 4 | |
| 6 | |
| 3 | |
| 1 | |
| 5 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 6 | |
| 5 | |
| 1 | |
| 1 | |
| 1 | |
Receptors, Epoprostenol/antagonists & inhibitors/*metabolism | 1 |
Epoprostenol/administration & dosage/*adverse effects/therapeutic use | 1 |
| 91 | |
| 2 | |
| 1 | |
| 1 | |
| 11 | |
| 100 | |
| 584 | |
| 1 | |
| 10 | |
| 2 | |
| 25 | |
| 43 | |
| 4 | |
| 6 | |
| 7 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 52 | |
| 4 | |
| 1 | |
| 3 | |
| 16 | |
| 3 | |
| 3 | |
| 1 | |
| 1 | |
| 20 | |
| 2 | |
| 9 | |
| 1 | |
| 4 | |
| 2 | |
| 2 | |
| 15 | |
| 13 | |
| 12 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 30 | |
| 3 | |
| 2 | |
| 1 | |
| 1 | |
| 2 | |